Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBPW), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biopharmaceutical company focused on a patent-pending sublingual delivery platform for drugs, nutraceuticals and supplements. The Aspire Biopharma news feed on Stock Titan brings together company announcements that explain how this platform is being advanced through clinical, regulatory, commercial and capital markets milestones.
Readers can follow detailed updates on Aspire Biopharma’s lead sublingual aspirin program, which the company is developing for the emergency treatment of suspected acute myocardial infarction. News items include results from pilot clinical trials comparing the sublingual aspirin formulation with chewed tablets, reports on rapid platelet inhibition, and disclosures about interactions with the U.S. Food and Drug Administration, such as pre‑IND meetings and regulatory guidance the company has received.
The feed also covers Aspire Biopharma’s corporate and listing developments, including communications about Nasdaq listing status, extensions granted by a Nasdaq Listing Qualifications Panel, transfer of the company’s stock to The Nasdaq Capital Market, and actions such as a 1‑for‑40 reverse stock split intended to help meet minimum bid price requirements. Investors can review how these steps fit into the company’s efforts to maintain its exchange listing and manage its capital structure.
In addition, Aspire Biopharma news highlights commercial activity around BUZZ BOMB™, the company’s proprietary sublingual caffeine supplement. Announcements describe product launches, sampling campaigns at fitness events, new manufacturing relationships, e‑commerce initiatives through a dedicated subsidiary, and brand partnerships such as the appointment of an elite ultra‑runner as a global brand ambassador. Updates on scientific team expansion, patent filings for the sublingual platform, and partnering discussions at major pharmaceutical conferences are also featured.
By reviewing this news stream, users can see how Aspire Biopharma presents the progress of its sublingual technology, from clinical data and regulatory planning to supplement commercialization and financing transactions. The page can be revisited regularly to monitor new press releases and disclosures as they are issued by the company.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company entered an agreement with TruLife Distribution on March 19, 2026, to manage national sales, distribution, and merchandising of BUZZ BOMB™.
The partnership targets natural, organic, specialty, and mass-merchandiser channels to expand retail footprint for the single‑serve 50mg dry‑powder caffeine stick packs.
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.
BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.
Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.
Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.
Aspire Biopharma (Nasdaq:ASBP) announced a strategic partnership with Microsize to develop a patent-pending, rapid-delivery sublingual alprazolam powder intended to bypass the digestive tract for faster anxiety relief.
Aspire plans a Phase 1 clinical trial in mid-2026, engaged Pace for formulation and stability work, and cites >15.8 million U.S. prescriptions in 2023 and a projected global alprazolam powder market of $55.84 billion by 2032.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.
Aspire Biopharma (NASDAQ:ASBP) regained full compliance with Nasdaq continued listing requirements on February 20, 2026.
The company met the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and earlier met the $1.00 minimum bid requirement under Rule 5550(a)(2). Nasdaq confirmed the matter is closed, but Aspire will remain under a Panel Monitor through February 18, 2027.
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a proprietary sublingual powder formulation of meclizine on February 17, 2026. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes and to support a 505(b)(2) regulatory path.
The company cites ~4.09 million U.S. prescriptions in 2023 and a $450M global meclizine market, projecting growth to $650M by 2032.
Aspire Biopharma (Nasdaq: ASBP) appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026, following the planned departures of Suren Ajjarapu and Donald G. Fell.
Balatsos brings 25+ years of capital markets and entrepreneurial experience and will serve on the Audit and Compensation Committees, supporting Aspire's strategy to reformulate established drugs using its patent-pending sublingual delivery platform.